4.8 Article Proceedings Paper

Targeted systemic delivery of siRNA to cervical cancer model using cyclic RGD-installed unimer polyion complex-assembled gold nanoparticles

Journal

JOURNAL OF CONTROLLED RELEASE
Volume 244, Issue -, Pages 247-256

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.jconrel.2016.08.041

Keywords

siRNA delivery; cRGD peptide; Unimer polyion complex; Gold nanoparticle; Cancer therapy

Funding

  1. Center of Innovation (COI) program from Japan Science and Technology Agency (JST)
  2. JSPS KAKENHI from Ministry of Education Culture, Sports, Science and Technology (MEXT) [25000006, 25282141]
  3. Project for Development of Innovative Research on Cancer Therapeutics (P-DIRECT)
  4. Basic Science and Platform Technology Program for Innovative Biological Medicine from Japan Agency for Medical Research and Development (AMED)
  5. Mochida Memorial Foundation for Medical and Pharmaceutical Research
  6. Grants-in-Aid for Scientific Research [25282141, 25000006, 16K11226] Funding Source: KAKEN

Ask authors/readers for more resources

For systemic delivery of small interfering RNA (siRNA) to solid tumors, we developed an actively-targeted unimer polyion complex-assembled gold nanoparticle (uPIC-AuNP) by a two-step assembling process. First is the monodispersed uPIC formation from the single molecules of therapeutic siRNA and the block catiomer, cyclic RGD (cRGD) peptide-installed poly(ethylene glycol)-block-poly(L-lysine) modified with lipoic acid (LA) at the.-end (cRGD-PEG-PLL-LA). Second is the surface decoration of a 20 nm-sized AuNP with uPICs. The cRGD-installed uPIC-AuNPs (cRGD-uPIC-AuNP) provided the targetability for selective binding to the cancer and cancer-related endothelial cellular surface, while regulating their size <50 nm with a quite narrow distribution. The targeting efficacy of the cRGD-uPIC-AuNP was confirmed by in vitro cellular uptake in cultured cervical cancer (HeLa) cells and in vivo tumor accumulation in a subcutaneous HeLa model after systemic administration, compared with a non-targeted control uPIC-AuNP. Due to the targetability of the ligand, the cRGD-uPIC-AuNP achieved the significantly enhanced gene silencing ability in the subcutaneous HeLa tumor. Ultimately, the systemic delivery of siRNA targeted for papilloma virus-derived E6 oncogene by cRGD-uPIC-AuNP significantly inhibited the growth of subcutaneous HeLa tumor. This research demonstrates that the bottom-up construction of nanocarriers using monodispersed building blocks can be employed as delivery platforms for RNA interference-based cancer therapy. (C) 2016 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available